Merck Millipore acquires rights for Biotest microbiology products
Merck Millipore now has exclusive rights to sell Biotest microbiology products in Australia and New Zealand.
In 2011, Merck Millipore acquired German company Biotest, an innovative industrial microbiology company with capabilities in ready-to-use media and hygiene monitoring. Its products are targeted at the pharmaceutical and food and beverage segments.
Biotest’s microbiology products, previously marketed by either of their two trading companies, Heipha and Hycon, are now exclusively available through Merck Millipore. Technical support for the products is also offered.
Vaxxas to advance its microarray patches for COVID vaccination
Vaxxas will receive AU$3.2m from BARDA to accelerate work advancing its high-density microarray...
Global competition targets 'undruggable' cancer protein
A new global competition offering over US$500,000 in prizes aims to spur drug discovery...
SMi Systems appoints Dr Ankur Mutreja as Senior Advisor
Mutreja was previously Head of Global South Partnerships at CEPI, where he was responsible for...
